Bosutinib

Product NDC
46708-311
11-digit product format
467080311
Labeler code
46708
Product ID
46708-311_17a3b455-b49a-492d-b6dc-47e96e6037ed
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Bosutinib
Dosage form
TABLET, FILM COATED
Route
ORAL
Labeler
Alembic Pharmaceuticals Limited
Application
ANDA209543
Marketing category
ANDA
Marketing start
2026-05-19
Substance
BOSUTINIB
Active strength
100 mg/1
Pharmacologic classes
Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Kinase Inhibitor [EPC]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Additional Listing Data#

Finished product
Yes
Brand name base
Bosutinib
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
BOSUTINIB100 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
Unii5018V4AEZ0
Rxcui1307624, 1307633

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b80921c3-d121-9271-9cc7-bf0fa96ea081Product name320260309

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
46708-311-35Bosutinib120 in 1 BOTTLETABLET, FILM COATED1202

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1307624bosutinib 100 MG Oral TabletPSN8f3e9739-8ec1-4ea9-b1bc-185fd07d84e42
1307633bosutinib 500 MG Oral TabletPSN8f3e9739-8ec1-4ea9-b1bc-185fd07d84e42
1307624bosutinib 100 MG Oral TabletSCD8f3e9739-8ec1-4ea9-b1bc-185fd07d84e42
1307633bosutinib 500 MG Oral TabletSCD8f3e9739-8ec1-4ea9-b1bc-185fd07d84e42
1307624bosutinib 100 MG (as bosutinib monohydrate 103.4 MG) Oral TabletSY8f3e9739-8ec1-4ea9-b1bc-185fd07d84e42
1307633bosutinib 500 MG (as bosutinib monohydrate 516.98 MG) Oral TabletSY8f3e9739-8ec1-4ea9-b1bc-185fd07d84e42

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
46708-311-3546708031135120 TABLET, FILM COATED in 1 BOTTLE (46708-311-35) 2026-05-19NoNoCurrent